These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Polymyxin resistance in Enterobacterales: overview and epidemiology in the Americas. Rodríguez-Santiago J; Cornejo-Juárez P; Silva-Sánchez J; Garza-Ramos U Int J Antimicrob Agents; 2021 Nov; 58(5):106426. PubMed ID: 34419579 [TBL] [Abstract][Full Text] [Related]
27. Emergence of Polymyxin Resistance in Clinical Klebsiella pneumoniae Through Diverse Genetic Adaptations: A Genomic, Retrospective Cohort Study. Macesic N; Nelson B; Mcconville TH; Giddins MJ; Green DA; Stump S; Gomez-Simmonds A; Annavajhala MK; Uhlemann AC Clin Infect Dis; 2020 May; 70(10):2084-2091. PubMed ID: 31513705 [TBL] [Abstract][Full Text] [Related]
28. Octapeptin C4 and polymyxin resistance occur via distinct pathways in an epidemic XDR Klebsiella pneumoniae ST258 isolate. Pitt ME; Cao MD; Butler MS; Ramu S; Ganesamoorthy D; Blaskovich MAT; Coin LJM; Cooper MA J Antimicrob Chemother; 2019 Mar; 74(3):582-593. PubMed ID: 30445429 [TBL] [Abstract][Full Text] [Related]
29. mcr-1 Colistin Resistance in ESBL-Producing Klebsiella pneumoniae, France. Caspar Y; Maillet M; Pavese P; Francony G; Brion JP; Mallaret MR; Bonnet R; Robin F; Beyrouthy R; Maurin M Emerg Infect Dis; 2017 May; 23(5):874-876. PubMed ID: 28418313 [TBL] [Abstract][Full Text] [Related]
30. First report of colistin resistance in an OXA-48- and a CTX-M-15 producing Klebsiella pneumoniae clinical isolate in Algeria due to PmrB protein modification and mgrB inactivation. Belbel Z; Lalaoui R; Bakour S; Nedjai S; Djahmi N; Rolain JM J Glob Antimicrob Resist; 2018 Sep; 14():158-160. PubMed ID: 30017731 [No Abstract] [Full Text] [Related]
31. Evaluation of Sensititre Broth Microdilution Plate for determining the susceptibility of carbapenem-resistant Klebsiella pneumoniae to polymyxins. Richter SS; Karichu J; Otiso J; Van Heule H; Keller G; Cober E; Rojas LJ; Hujer AM; Hujer KM; Marshall S; Perez F; Rudin SD; Domitrovic TN; Kaye KS; Salata R; van Duin D; Bonomo RA Diagn Microbiol Infect Dis; 2018 May; 91(1):89-92. PubMed ID: 29456071 [TBL] [Abstract][Full Text] [Related]
32. Polymyxin resistance caused by mgrB inactivation is not associated with significant biological cost in Klebsiella pneumoniae. Cannatelli A; Santos-Lopez A; Giani T; Gonzalez-Zorn B; Rossolini GM Antimicrob Agents Chemother; 2015 May; 59(5):2898-900. PubMed ID: 25691629 [TBL] [Abstract][Full Text] [Related]
34. A retrospective study on mcr-1 in clinical Escherichia coli and Klebsiella pneumoniae isolates in China from 2007 to 2016. Liu X; Wang Y; Cui L; Li Y; Xue F; Liu J; Wang L; Shen Y; Lv Y J Antimicrob Chemother; 2018 Jul; 73(7):1786-1790. PubMed ID: 29912359 [TBL] [Abstract][Full Text] [Related]
35. Outbreak of colistin-resistant carbapenemase-producing Klebsiella pneumoniae in Tunisia. Mansour W; Haenni M; Saras E; Grami R; Mani Y; Ben Haj Khalifa A; El Atrouss S; Kheder M; Fekih Hassen M; Boujâafar N; Bouallegue O; Madec JY J Glob Antimicrob Resist; 2017 Sep; 10():88-94. PubMed ID: 28711559 [TBL] [Abstract][Full Text] [Related]
36. Spread of Carbapenem and Colistin-Resistant Klebsiella pneumoniae ST512 Clinical Isolates in Israel: A Cause for Vigilance. Lalaoui R; Bakour S; Livnat K; Assous MV; Diene SM; Rolain JM Microb Drug Resist; 2019; 25(1):63-71. PubMed ID: 30129868 [TBL] [Abstract][Full Text] [Related]